Table 5.
Determinants of aldosterone breakthrough at 1 year (i.e., serum aldosterone level increase greater than 10% over baseline values) versus serum aldosterone decrease (>10% below baseline values) associated with aldosterone breakthrough, including the significant interaction with changes of sodium intake during follow-up, using multivariate logistic regression analysis
| Variables | Increase of Serum Aldosterone Levels>10% over Baseline Values (n=158 points) Versus Decrease of Serum Aldosterone Levels>10% below Baseline Values (n=320 points) | |
|---|---|---|
| Model 1a Odds Ratio (95% CI) | Model 2b Odds Ratio (95% CI) | |
| Baseline characteristics | ||
| Serum aldosterone (log mg/dl) | 0.22 (0.17 to 0.34) | 0.23 (0.15 to 0.35) |
| Systolic BP (mmHg) | 1.02 (1.00 to 1.03) | 1.01 (0.99 to 1.03) |
| Serum potassium (mmol/L) | 0.53 (0.32 to 0.86) | 0.64 (0.38 to 1.07) |
| Significant decrease from baseline to 1 yr | ||
| Systolic BP (mmHg) | — | 1.02 (1.00 to 1.03) |
| Serum potassium (mmol/L) | — | 0.78 (0.48 to 1.27) |
| Estimated GFR (log ml/min per 1.73 m2) | — | 6.44 (2.31 to 17.95) |
| Na intake (Mann’s formula; log mmol/d) | ||
| Subgroup with increased Na intake | — | 1.26 (0.12 to 13.3) |
| Subgroup with decreased Na intake | — | 4.45 (1.38 to 14.3) |
| Angiotensin II receptor blocker treatment | ||
| Losartan versus telmisartan | — | 1.60 (1.04 to 2.53) |
95% CI, confidence interval.
After adjustment for baseline age, sex, ethnicity, smoking status, glycosylated hemoglobin, sodium intake, urinary albumin creatinine ratio, estimated GFR, and additional antihypertensive treatment.
With adjustment for glycosylated hemoglobin, urinary albumin creatinine ratio, sodium intake, and additional antihypertensive treatment variations (in addition to the parameters included in model 1).